MACROGENICS INC
MACROGENICS INC (MGNX): 32 pipeline candidates · 2 upcoming catalysts · ~9 mo cash runway · 21 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.5 months
D/E 9.28 · 0% dilution
Lead: Approved
32 candidates
2 upcoming, next in ~2893d
N/A
A transparent, data-derived signal for MACROGENICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$251.7M
Cash
$66.5M
Quarterly Burn
$35.8M
Runway
8.5 mo
Revenue
$20.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (32 candidates)
| Drug | Phase |
|---|---|
| Abiraterone | Phase 2 |
| Enoblituzumab | Phase 2 |
| Enoblituzumab Schedule 1 | Phase 2 |
| Enoblituzumab Schedule 2 | Phase 2 |
| Enzalutamide | Phase 2 |
| Flotetuzumab | Phase 2 |
| IMGC936 | Phase 1 |
| Lorigerlimab | Phase 2 |
| MARGENZA | Approved |
| margetuximab | Phase 3 |
Showing 10 of 32 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
109
Total value held
$125.6M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 6,012,000 | $17.4M |
| vanguard capital management llc | 5,307,706 | $15.3M |
| renaissance technologies llc | 2,963,559 | $8.6M |
| millennium management llc | 2,794,357 | $8.1M |
| two sigma investments, lp | 2,527,829 | $7.3M |
| bank of america corp /de/ | 2,401,814 | $6.9M |
| marshall wace, llp | 2,025,526 | $5.9M |
| ra capital management, l.p. | 1,864,176 | $5.4M |
| wasatch advisors lp | 1,559,701 | $4.5M |
| vanguard portfolio management llc | 1,208,775 | $3.5M |
Showing top 10 of 109 institutional holders of MACROGENICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MACROGENICS INC's pipeline?
MACROGENICS INC (MGNX) has 32 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MACROGENICS INC's lead drug candidate?
MACROGENICS INC's most advanced tracked candidate is Abiraterone (Phase 2) for Castration-Resistant Prostatic Cancer.
What is MACROGENICS INC's next catalyst?
MACROGENICS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: YONSA" — expected May 20, 2034.
What is MACROGENICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MACROGENICS INC has approximately 8.5 months of cash runway.
What is MACROGENICS INC's market capitalization?
MACROGENICS INC's market capitalization is approximately $251.7M.
Get the full picture on MACROGENICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.